All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Antengene, the most common co-covered peer. The 6 average consequence score is below the beat benchmark of 6.3 in the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about TCE
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Antengene, the most common co-covered peer. The 6 average consequence score is below the beat benchmark of 6.3 in the same window. They are better corroborated than the beat average, carrying 3 original sources each against 2.9 for the same window. TCE appears in 1 tracked Healthcare story from March 20, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering TCE. Shared-story counts are live from our verified record — not editorial picks.
Antengene Corporation has reported its 2025 full-year financial results, highlighted by its first T-cell engager (TCE) out-licensing agreement. This milestone validates the company's proprietary platform and establishes a clear financial trajectory toward achieving profitability by 2026.